2 results match your criteria: "CSIC and CIBERONC. Institute of Biomedical Research of Salamanca (IBSAL)[Affiliation]"
JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.
Biomed Pharmacother
December 2021
Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Farmacología Molecular y Traslacional (BIOPharm), Universidad de Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain. Electronic address:
Chronic myelogenous leukemia (CML) is a hematological malignancy that highly depends on the BCR-ABL1/STAT5 signaling pathway for cell survival. First-line treatments for CML consist of tyrosine kinase inhibitors that efficiently target BCR-ABL1 activity. However, drug resistance and intolerance are still therapeutic limitations in Ph+ cells.
View Article and Find Full Text PDFAltered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma.
J Exp Clin Cancer Res
August 2021
Instituto de Biología Molecular y Celular del Cáncer, CSIC and CIBERONC. Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Article Synopsis
- Treatment advancements for renal cancer include kinase inhibitors and immunotherapies, but the disease remains incurable in advanced stages, prompting a study on other receptor tyrosine kinases (RTKs) beyond those currently targeted.
- Researchers investigated the activation of 49 RTKs in kidney tissue samples and found that the epidermal growth factor receptor (EGFR) and its ligand TGFα are significantly activated in tumors, with unique characteristics in how TGFα is expressed.
- Targeting the EGFR-TGFα axis inhibited cancer cell proliferation, suggesting this pathway is crucial in kidney cancer's pathology, and highlights a potential therapeutic strategy involving antibody drug conjugates that can target the distinctive membrane-anchored form of TGFα in tumors.